<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0401221553
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HEMABO 24MG/1.2ML 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PLERIXAFOR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11847.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hemabo contains the active substance plerixafor which blocks a protein on the surface of blood stem cells. This protein &quot;ties&rdquo; blood stem cells to the bone marrow. Plerixafor improves the release of stem cells into the blood stream (mobilisation). The stem cells can then be collected by a machine that separates blood constituents (apheresis machine), and subsequently frozen and stored until your transplant.</p><p>If mobilisation is poor, Hemabo is used to help collect blood stem cells from the patient, for collection, storage and reintroduction (transplantation),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adults who have lymphoma (a cancer of the white blood cells) or multiple myeloma (a cancer that affects plasma cells in the bone marrow).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children age 1 to less than 18 years of age with lymphoma or solid tumors.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp; Do not take Hemabo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to plerixafor or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions</p><p>Talk to your doctor before using Hemabo. Tell your doctor:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had any heart problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems. Your doctor may adjust the dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have high white blood cell counts.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low platelet counts.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of feeling faint or lightheaded on standing or sitting or have fainted before upon injections.</p><p>Your doctor may perform regular blood tests to monitor your blood cell count.</p><p>It is not recommended to use Hemabo for stem cell mobilization if you have leukaemia (a cancer of the blood or bone marrow).</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>You should not use Hemabo if you are pregnant, since there is no experience with plerixafor in pregnant women. It is important to tell your doctor if you are, think you may be or are planning to become pregnant. It is recommended to use contraception if you are of child-bearing age.</p><p>You should not breast-feed if you are using Hemabo, since it is not known if plerixafor is excreted in human milk.</p><p>Driving and using machines</p><p>Hemabo may cause dizziness and fatigue. Therefore, you should avoid driving if you feel dizzy, tired or unwell.</p><p>Hemabo contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &#39;sodium-free&#39;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your medicine will be injected by a doctor or a nurse.</p><p>You will first receive G-CSF, then you will be given Hemabo</p><p>Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony stimulating factor). G-CSF will help Hemabo to work properly in your body. If you want to know more about G-CSF ask your doctor and read the corresponding package leaflet.</p><p>How much Hemabo is given?</p><p>The recommended adult dose is either a 20 mg (fixed dose) or 0.24 mg/kg body weight/day. The recommended dose for children, 1 to less than 18 years of age is 0.24 mg/kg of bodyweight/day. Your dose will depend on your body weight, which should be measured the week before you receive your first dose. If you have moderate or severe kidney problems, your doctor will reduce the dose.</p><p>How is Hemabo given?</p><p>Hemabo is given by subcutaneous injection (under your skin).</p><p>When is Hemabo given for the first time?</p><p>You will receive your first dose 6 to 11 hours before apheresis (collection of your blood stem cells).</p><p>How long will Hemabo be given?</p><p>Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have been collected for your transplant. In a few cases, enough stem cells may not be collected, and the collection attempt will be stopped.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Please tell your doctor immediately if,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortly after receiving Hemabo, you experience rash, swelling around the eyes, shortness of breath or lack of oxygen, feeling lightheaded on standing or sitting, feeling faint or fainting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have pain in the upper left abdomen (belly) or your left shoulder</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, nausea (feeling sick), injection site redness or irritation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell count by laboratory test (anaemia in children)</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, feeling tired or unwell</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flatulence, constipation, indigestion, vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach symptoms such as pain, swelling or discomfort</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth, numbness around the mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating, generalised redness of the skin, joint pains, pains in muscles and bones</p><p>Uncommon side effects (may affect up to 1 in 1 00 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as skin rash, swelling around the eyes, shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactic reactions, including anaphylactic shock</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams, nightmares</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rarely, gastrointestinal side effects may be severe (diarrhoea, vomiting, stomach pain and nausea).</p><p>Heart attacks</p><p>In clinical trials, patients with risk factors for a heart attack uncommonly suffered heart attacks after being given plerixafor and G-CSF. Please inform your doctor immediately if you experience chest discomfort.</p><p>Pins and needles and numbness</p><p>Pins and needles and numbness are common in patients being treated for cancers. About one in five patients suffered from these feelings. However, these effects do not seem to occur more frequently when you use plerixafor. You may also have an increase in white blood cells count (leucocytosis), in your blood tests.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and vial.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After opening the vial, Hemabo should be used immediately.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. The pharmacist will throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is plerixafor. Each ml solution for injection contains 20mg of plerixafor. Each vial contains 24 mg plerixafor in 1.2 ml solution.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium chloride, hydrochloric acid, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Hemabo is a clear colourless to pale yellow colour solution and free from visible particulate matter in 2 mL Type-I clear glass vial with 13 mm grey rubber stopper and sealed with 13 mm aluminium seal having blue colour polypropylene disc.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company Tadawi Biomedical-KSA Riyadh, Sudair Industrial Area, Zone A, Road 11, Factory 107,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هيمابو على مادة plerixafor الفعالة التي تحصر بروتيناً على سطح الخلايا الجذعية الدموية يعمل على ربط هذه الخلايا بنخاع العظم، وبذلك يحسن plerixafor من إطلاق الخلايا الجذعية إلى مجرى الدم (تحريك)، ويمكن أن تجمع هذه الخلايا الجذعية بعد ذلك بواسطة آلة تعمل على فصل مكونات الدم (جهاز الفصادة) ومن ثم تجمد لاحقاً وتخزن حتى موعد الزرع.</p><p dir="RTL">يستخدم هيمابو للمساعدة في جمع خلايا الدم الجذعية من المريض، إذا كانت عملية &quot;تحريك&quot; الخلايا ضعيفة وذلك بغرض جمعها وتخزينها وإعادة إطلاقها لاحقاً عند زرع نخاع العظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عند البالغين المصابين باللمفوما (أحد سرطانات خلايا الدم البيضاء) أو الورم النقوي العديد (سرطان يصيب الخلايا البلازمية في نقي العظم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عند الأطفال المصابين بلمفوما أو أورام صلبة بعمر يتراوح بين سنة إلى أقل من 18 سنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم هيمابو </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتحسس من plerixafor أو أي من المكونات الأخرى لهذا الدواء (مذكورة في القسم 6)</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل استخدام هيمابو.</p><p dir="RTL">أخبر طبيبك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو كان لديك مشاكل قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل كلوية، حيث يتوجب على طبيبك حينها تعديل الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تعداد كريات بيضاء مرتفع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تعداد صفيحات منخفض. &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ شعور بالدوار أو خفة في الرأس عند الوقوف أو الجلوس أو تعرضت للإغماء او الدوار سابقاً عند إعطائك الحقن.</p><p dir="RTL">ربما يقوم طبيبك بإجراء تحاليل دموية منتظمة لمراقبة تعداد الخلايا في دمك.</p><p dir="RTL">لا يوصى باستعمال هيمابو لتحريك خلايا الدم الجذعية إذا كان لديك &quot;لوكيميا&quot; (أحد سرطانات الدم أو نخاع العظم).</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا تستخدمي هيمابو إن كنتِ حاملاً، لأنه لا توجد تجارب على بليريكسافورplerixafor &nbsp;عند النساء الحوامل. من المهم أن تخبري طبيبك إذا كنتِ حاملاً، أو تعتقدين أنك حامل، أو تخططين للحمل. ونوصيكِ باستخدام وسائل منع الحمل إن كنت في سن الإنجاب.</p><p dir="RTL">لا تقومي بإرضاع طفلك إن كنت تستخدمين الهيمابو Hemabo، لأنه من غير المعروف إن كان بليريكسافور plerixafor يفرز في حليب البشر.</p><p dir="RTL"><strong>القيادة واستخدام المركبات</strong></p><p dir="RTL">يمكن للهيمابو Hemabo أن يسبب الشعور بالدوخة والتعب، لذا يجب عليك تجنب القيادة إن أحسست بالدوخة أو شعرت أنك لست على ما يرام.</p><p dir="RTL"><strong>يحتوي الهيمابو على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ميلي مول من الصوديوم (ما يعادل 23مغ) للجرعة الواحدة، أي أنه خالٍ من الصوديوم فعلياً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم الطبيب أو الممرضة بحقنك بالدواء.</p><p dir="RTL"><strong>سوف </strong><strong>تتلقى</strong><strong> بدايةً العامل المحفز لتكاثر الخلايا المحببه</strong><strong>G-CSF </strong><strong>&nbsp;</strong><strong>ثم ستعطى الهيمابو</strong></p><p dir="RTL">تبدأ عملية التحريك أو &quot;التجنيد&quot; Mobilisation فور إعطائك دواءً آخرَ يدعى ب العامل المحفز لتكاثر الخلايا المحببهG-CSF &nbsp;لأول مرة. سيساعد العامل المحفز لتكاثر الخلايا المحببه الهيمابو للعمل كما ينبغي في جسمك. إذا أردت معرفة المزيد عن G-CSF اسأل طبيبك وقم بقراءة نشرة العلبة الموافقة.</p><p dir="RTL"><strong>كم هو مقدار هيمابو الذي يعطى؟</strong></p><p dir="RTL">الجرعة الموصى بها للبالغين إما 20مغ (جرعة ثابتة) أو 0.24مغ/لكل كغ من وزن الجسم/ في اليوم. الجرعة الموصى بها للأطفال من عمر السنة لأقل من 18 سنة هي 0.24 مع/ لكل كغ من وزن الجسم/ في اليوم. تعتمد كمية الجرعة المعطاة لك على وزن جسمك الذي يجب قياسه قبل أسبوع واحد من تلقيك لجرعتك الأولى. سيقوم طبيبك بتخفيض جرعة الدواء إن كنت تعاني من مشاكل كلوية متوسطة إلى شديدة.</p><p dir="RTL"><strong>ما هي طريقة إعطاء الهيمابو؟</strong></p><p dir="RTL">يُعطى الهيمابو حقناً تحت الجلد.</p><p dir="RTL"><strong>متى تُعطى الجرعة الأولى من الهيمابو؟</strong></p><p dir="RTL">سوف تتلقى جرعتك الأولى قبل 6-11ساعة من عملية الفِصادة (جمع خلاياك الدموية الجذعية).</p><p dir="RTL"><strong>ما هي مدة إعطاء الهيمابو؟</strong></p><p dir="RTL">ستستمر المعالجة لمدة 2إلى 4 أيام متتالية (حتى 7 أيام في بعض الحالات) حتى يتم جمع العدد الكافي من الخلايا الجذعية لزرعها عندك. قد لا يُجمع في بعض الحالات ما يكفي من الخلايا الجذعية وتوقف حينها محاولة الجمع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن لهذا الدواء أن يتسبب ببعض التأثيرات الجانبية كما هو الحال بالنسبة لجميع الأدوية، لكن هذه التأثيرات لا تحدث عند جميع الأشخاص الذين يتلقونه على أية حال.</p><p dir="RTL"><strong>قم بإخبار طبيبك على الفور رجاءً إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عانيت من طفح جلدي بعد فترة قصيرة من تلقيك للدواء، أو عانيت من تورم حول العينين، أو ضيق في التنفس أو نقص الأوكسجين، أو الشعور بخفة الرأس عند الوقوف أو الجلوس، أو الشعور بالغشي أو الإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حدث لديك ألم في الربع العلوي الأيسر من البطن (المعدة) أو الكتف الأيسر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة جداً (ربما تُؤثر على أكثر من شخص من كل 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، الغثيان، تهيج أو احمرار موقع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدم الحمراء بالفحص المخبري (فقر دم عند الأطفال).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (ربما تُؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، الشعور بالتعب أو التوعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن، والإمساك، وعسر الهضم، والإقياء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أعراض معدية مثل الألم أو الانتفاخ أو عدم الشعور بالراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، أو النمَل حول الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التعرق، واحمرار الجلد المعمم، وآلام المفاصل، والألم في العضلات والعظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (ربما تُؤثر على شخص واحد من كل 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية مثل الطفح الجلدي، والتورم حول العينين، وضيق النفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تأقية بما فيها الصدمة التأقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أحلام مزعجة، كوابيس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات جانبية مَعدية مِعوية بشكل نادر قد تكون شديدة (إسهال، وإقياء، وألم في المعدة، وشعور بالغثيان).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النوبات القلبية:</strong></p><p dir="RTL">بينت التجارب السريرية أن الأشخاص الذين لديهم عوامل خطورة للنوبات القلبية عانوا بشكل استثنائي من نوبات قلبية بعد أخذهم plerixafor و G-CSF. رجاءً أخبر طبيبك فوراً إذا عانيت من انزعاج في الصدر.</p><p dir="RTL"><strong>الإحساس بوخز الدبابيس والإبر والخدر:</strong></p><p dir="RTL">هذه الأعراض شائعة عند الأشخاص الذين يعالجون من أجل السرطان، ويعاني نحو شخص من كل 5 أشخاص من هذا الشعور، لكن لا يبدو أن هذه الأعراض تحدث أكثر عند استخدامك plerixafor. قد تُظهر فحوصات الدم لديك ازدياداً في عدد الكريات البيضاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حافظ على الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المسجل على الكرتونة أو الزجاجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام هيمابو بعد فتح الزجاجة مباشرةً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي دواء برميه مع الماء المستعمل أو فضلات المنزل، سوف يقوم الصيدلاني بالتخلص من الدواء الذي لم تعد تستخدمه، وستساهم هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي plerixafor، ويحتوي كل مل من محلول الحقن على 20 مغ من plerixafor، وتحتوي كل زجاجة 24 مغ plerixafor في 1.2مل من المحلول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات هي كلوريد الصوديوم، وحمض كلور الماء، وهيدروكسيد الصوديوم، وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هيمابو هو محلول عديم اللون إلى اللون الأصفر الباهت، لا يحتوي على جسيمات أو مواد مرئية، موضوع في زجاجة شفافة من النمط الأول تتسع لـ 2 مل، مع سدَّادة مطاطية رمادية تقيس 13 مم، وتُختم بغطاء من الألمنيوم يقيس 13 مم له قرص أزرق اللون من البولي بروبيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>أ&zwnj;-</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>مالك حقوق التسويق والتغليف الثانوي</em><em>: </em></p><p dir="RTL">شركة بوستن اونكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL"><em>ب&zwnj;-</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>التصنيع الكامل والتغليف الأولي</em><em>: </em></p><p dir="RTL">مختبرات أم أس أن الخاصة المحدودة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hemabo
Plerixafor Injection 24 mg/1.2 ml

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of solution contains 20 mg plerixafor.
Each vial contains 24 mg plerixafor in 1.2 ml solution.
Excipients with known effect:
Each ml contains approximately 3 mg of sodium. For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
A clear colorless to pale yellow color solution and free from visible particulate matter

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult patients</u></p><p>Hemabo is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).</p><p><u>Paediatric patients (1 to less than 18 years)</u></p><p>Hemabo is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma <u>or</u> solid malignant tumours, either:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hemabo therapy should be initiated and supervised by a physician experienced in oncology and/or haematology. The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.</p><p>Age over 60 and/ or prior myelosuppressive chemotherapy and/or extensive prior chemotherapy and/or a peak circulating stem cell count of less than 20 stem cells/microliter, have been identified as predictors of poor mobilisation.</p><p><u>Posology</u> <u>Adult</u></p><p>The recommended daily dose of plerixafor by subcutaneous injection (SC) is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing &le; 83 kg (see section</p><p>5.2).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.24 mg/kg of body weight for patients weighing &gt; 83 kg.</p><p><u>Paediatric (1 to less than 18 years)</u></p><p>The recommended daily dose of plerixafor by subcutaneous injection (SC) is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.24 mg/kg of body weight (see section 5.1).</p><p>Each vial of plerixafor is filled to deliver 1.2 ml of 20 mg/ml plerixafor aqueous solution for injection containing 24 mg of plerixafor.</p><p>Plerixafor has to be drawn up into a syringe size type which should be selected according to the weight of the patient.</p><p>&nbsp;</p><p>For low weight patients, up to 45 kg of body weight, 1 ml syringes for use in infant patients can be used. This type of syringe has major graduations for 0.1 ml and minor graduations for 0.01 ml and therefore is suitable to administer plerixafor, at a dose of 240 &micro;g/kg, to paediatric patients of at least 9 kg body weight.</p><p>For patients of more than 45 kg, a1 ml or 2 ml syringe with graduations that allow a volume to</p><p>0.1 ml to be measured can be used.</p><p>It should be administered by subcutaneous injection 6 to 11 hours prior to initiation of each apheresis following 4 day pre-treatment with G-CSF. In clinical trials, plerixafor has been commonly used for 2 to 4 (and up to 7) consecutive days.</p><p>The weight used to calculate the dose of plerixafor should be obtained within 1 week before the first dose of plerixafor. In clinical studies, the dose of plerixafor has been calculated based on body weight in patients up to 175% of ideal body weight. Plerixafor dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated. Ideal body weight can be determined using the following equations:</p><p>Male(kg):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50 + 2.3 x ((Height (cm) x 0.394) &ndash; 60);</p><p>Female(kg):&nbsp; 45.5 + 2.3 x ((Height (cm) x 0.394) &ndash; 60).</p><p>Based on increasing exposure with increasing body weight, the plerixafor dose should not exceed 40 mg/day.</p><p><em><u>Recommended concomitant medicinal products</u></em></p><p>In pivotal clinical studies supporting the use of plerixafor, all patients received daily morning doses of 10 &mu;g/kg G-CSF for 4 consecutive days prior to the first dose of plerixafor and on each morning prior to apheresis.</p><p>&nbsp;</p><p><em><u>Special populations</u> Renal impairment</em></p><p>Patients with creatinine clearance 20-50 ml/min should have their dose of plerixafor reduced by one-third to 0.16 mg/kg/day (see section 5.2). Clinical data with this dose adjustment are limited. There is insufficient clinical experience to make alternative posology recommendations for patients with a creatinine clearance &lt;20 ml/min, as well as to make posology recommendations for patients on haemodialysis.</p><p>Based on increasing exposure with increasing body weight the dose should not exceed 27 mg/day if the creatinine clearance is lower than 50 ml/min.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of plerixafor in children (- 1 to less than 18 years) were studied in an open label, multicenter, controlled study (see sections 4.8, 5.1, and 5.2).</p><p><em>Elderly patients (&gt; 65 years old)</em></p><p>No dose modifications are necessary in elderly patients with normal renal function. Dose adjustment in elderly patients with creatinine clearance &le; 50 ml/min is recommended (see Renal impairment above). In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age.</p><p><u>Method of administration</u></p><p>Hemabo is for subcutaneous injection. Each vial is intended for single use only.</p><p>Vials should be inspected visually prior to administration and not used if there is particulate matter or discolouration. Since Hemabo is supplied as a sterile, preservative-free formulation, aseptic technique should be followed when transferring the contents of the vial to a suitable syringe for subcutaneous administration (see section 6.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tumour cell mobilisation in patients with lymphoma and multiple myeloma</u></p><p>When plerixafor is used in conjunction with G-CSF for haematopoietic stem cell mobilisation in patients with lymphoma or multiple myeloma&sbquo; tumour cells may be released from the marrow and subsequently collected in the leukapheresis product. Results showed that, in case tumour cells are mobilised, the number of tumour cells mobilised is not increased upon plerixafor plus G-CSF compared to G-CSF alone.</p><p><u>Tumour cell mobilisation in leukaemia patients</u></p><p>In a compassionate use programme, plerixafor and G-CSF have been administered to patients with acute myelogenous leukaemia and plasma cell leukaemia. In some instances, these patients experienced an increase in the number of circulating leukaemia cells. For the purpose of haematopoietic stem cell mobilisation, plerixafor may cause mobilisation of leukaemic cells and subsequent contamination of the apheresis product. Therefore, plerixafor is not recommended for haematopoietic stem cell mobilisation and harvest in patients with leukaemia.</p><p><u>Haematological effects</u></p><p><em>Hyperleukocytosis</em></p><p>Administration of plerixafor in conjunction with G-CSF increases circulating leukocytes as well as haematopoietic stem cell populations. White blood cell counts should be monitored during plerixafor therapy. Clinical judgment should be exercised when administering plerixafor to patients with peripheral blood neutrophil counts above 50 x 10<sup>9</sup>/L.</p><p><em>Thrombocytopenia</em></p><p>Thrombocytopenia is a known complication of apheresis and has been observed in patients receiving plerixafor. Platelet counts should be monitored in all patients receiving plerixafor and undergoing apheresis.</p><p><u>Allergic reactions</u></p><p>Plerixafor has been uncommonly associated with potential systemic reactions related to subcutaneous injection such as urticaria, periorbital swelling, dyspnoea, or hypoxia (see section 4.8). Symptoms responded to treatments (e.g., antihistamines, corticosteroids, hydration or supplemental oxygen) or resolved spontaneously. Cases of anaphylactic reactions, including anaphylactic shock, have been reported from world-wide post-marketing experience. Appropriate precautions should be taken because of the potential for these reactions.</p><p><u>Vasovagal reactions</u></p><p>Vasovagal reactions, orthostatic hypotension, and/or syncope can occur following subcutaneous injections (see section 4.8). Appropriate precautions should be taken because of the potential for these reactions.</p><p><u>Effect on the spleen</u></p><p>In preclinical studies, higher absolute and relative spleen weights associated with extramedullary haematopoiesis were observed following prolonged (2 to 4 weeks) daily plerixafor subcutaneous administration in rats at doses approximately 4 fold higher than the recommended human dose.</p><p>The effect of plerixafor on spleen size in patients has not been specifically evaluated in clinical studies. Cases of splenic enlargement and/or rupture have been reported following the administration of Plerixafor in conjunction with growth factor G-CSF. Individuals receiving Plerixafor in conjunction with G-CSF who report left upper abdominal pain and/or scapular or shoulder pain should be evaluated for splenic integrity.</p><p><u>Sodium</u></p><p>Hemabo contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &#39;sodium- free&#39;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. <em>In vitro </em>tests showed that plerixafor was not metabolised by P450 CYP enzymes, did not inhibit or induce P450 CYP enzymes. Plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an <em>in vitro </em>study.</p><p>&nbsp;</p><p>In clinical studies of patients with Non-Hodgkin&#39;s lymphoma, the addition of rituximab to a mobilisation regimen of plerixafor and G-CSF did not impact patient safety or CD34+ cell yield.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of childbearing potential have to use effective contraception during treatment.</p><p><u>Pregnancy</u></p><p>There are no adequate data on the use of plerixafor in pregnant women.</p><p>Based on the pharmacodynamic mechanism of action, plerixafor is suggested to cause congenital malformations when administered during pregnancy. Studies in animals have shown teratogenicity (see section 5.3). Hemabo should not be used during pregnancy unless the clinical condition of the woman requires treatment with plerixafor.</p><p><u>Breast-feeding</u></p><p>It is unknown whether plerixafor is excreted in human milk. A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with Hemabo.</p><p><u>Fertility</u></p><p>The effects of plerixafor on male and female fertility are not known (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hemabo may influence the ability to drive and use machines. Some patients have experienced dizziness, fatigue or vasovagal reactions; therefore caution is advised when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Safety data for plerixafor in conjunction with G-CSF in oncology patients with lymphoma and multiple myeloma were obtained from 2 placebo-controlled Phase III studies (301 patients) and 10 uncontrolled Phase II studies (242 patients). Patients were primarily treated with daily doses of 0.24 mg/kg plerixafor by subcutaneous injection. The exposure to plerixafor in these studies ranged from 1 to 7 consecutive days (median = 2 days).</p><p>In the two Phase III studies in non-Hodgkin&#39;s lymphoma and multiple myeloma patients (AMD3100-3101 and AMD3100-3102, respectively), a total of 301 patients were treated in the plerixafor and G-CSF group and 292 patients were treated in the placebo and G-CSF group. Patients received daily morning doses of G-CSF 10 &mu;g/kg for 4 days prior to the first dose of plerixafor or placebo and on each morning prior to apheresis. Adverse reactions that occurred more frequently with plerixafor and G-CSF than placebo and G-CSF and were reported as related in &ge;1% of the patients who received plerixafor, during haematopoietic stem cell mobilisation and apheresis and prior to chemotherapy/ablative treatment in preparation for transplantation are shown in Table 1.</p><p>From chemotherapy/ablative treatment in preparation of transplantation through 12 months post-transplantation, no significant differences in the incidence of adverse reactions were observed across treatment groups.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed by System Organ Class and frequency. Frequencies are defined according to the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>Table 1. Adverse reactions occurring more frequently with plerixafor than placebo and considered related to plerixafor during mobilisation and apheresis in phase III studies</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Splenomegaly, splenic rupture (see section 4.4)<sup>**</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Allergic reaction<sup>*</sup></p><p>Anaphylactic reactions, including anaphylactic shock (see section 4.4)<sup>**</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abnormal dreams, nightmares</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, abdominal pain, stomach discomfort, dyspepsia, abdominal distention, constipation, flatulence, hypoaesthesia oral, dry mouth</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperhidrosis, erythema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia, musculoskeletal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Injection and infusion site reactions</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue, malaise</p></td></tr></tbody></table><p><em>* </em>The frequency of allergic reactions presented is based on adverse reactions that occurred in the oncology studies (679 patients). Events included one or more of the following: urticaria (n = 2), periorbital swelling (n = 2), dyspnoea (n = 1) or hypoxia (n = 1). These events were generally mild or moderate and occurred within approximately 30 min after plerixafor administration.</p><p>** From post-marketing experience</p><p>&nbsp;</p><p>The adverse reactions reported in patients with lymphoma and multiple myeloma who received plerixafor in the controlled Phase III studies and uncontrolled studies, including a Phase II study of plerixafor as monotherapy for haematopoietic stem cell mobilisation, are similar. No significant differences in the incidence of adverse reactions were observed for oncology patients by disease, age, or gender.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Myocardial infarction</em></p><p>In clinical studies, 7 of 679 oncology patients experienced myocardial infarctions after haematopoietic stem cell mobilisation with plerixafor and G-CSF. All events occurred at least 14 days after last plerixafor administration. Additionally, two female oncology patients in the compassionate use programme experienced myocardial infarction following haematopoietic stem cell mobilisation with plerixafor and G-CSF. One of these events occurred 4 days after last plerixafor administration. Lack of temporal relationship in 8 of 9 patients coupled with the risk profile of patients with myocardial infarction does not suggest plerixafor confers an independent risk for myocardial infarction in patients who also receive G-CSF.</p><p><em>Hyperleukocytosis</em></p><p>White blood cell counts of 100 x 10<sup>9</sup>/L or greater were observed, on the day prior to or any day of apheresis, in 7% patients receiving plerixafor and in 1% patients receiving placebo in the Phase III studies. No complications or clinical symptoms of leukostasis were observed.</p><p><em>Vasovagal reactions</em></p><p>In plerixafor oncology and healthy volunteer clinical studies, less than 1% of subjects experienced vasovagal reactions (orthostatic hypotension and/or syncope) following subcutaneous administration of plerixafor doses &le;0.24 mg/kg. The majority of these events occurred within 1 hour of plerixafor administration.</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>In plerixafor clinical studies of oncology patients, there have been rare reports of severe gastrointestinal events, including diarrhoea, nausea, vomiting, and abdominal pain.</p><p><em>Paraesthesia</em></p><p>Paraesthesia is commonly observed in oncology patients undergoing autologous transplantation following multiple disease interventions. In the placebo-controlled Phase III studies, the incidence of paraesthesia was 20.6% and 21.2% in the plerixafor and placebo groups, respectively.</p><p><em>Elderly patients</em></p><p>In the two placebo-controlled clinical studies of plerixafor, 24% of patients were &ge; 65 years old. No notable differences in the incidence of adverse reactions were observed in these elderly patients when compared with younger ones.</p><p><em>Paediatric population</em></p><p>Thirty patients were treated with 0.24 mg/kg of Plerixafor in an open label, multicenter, controlled study (DFI 12860) (see section 5.1).</p><p>The safety profile in this paediatric study was consistent with what has been observed in adults.</p><p>To report any side effect(s):</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Saudi Arabia</u></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="docshape4" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:125.05pt;margin-top:4.6pt;width:371.55pt;
  height:73pt;z-index:-15728640;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight="1pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:3.5pt;margin-right:0in;margin-bottom:
     0in;margin-left:24.15pt;margin-bottom:.0001pt'><span style='font-size:
     12.0pt;mso-bidi-font-size:11.0pt'>The<span style='letter-spacing:-.2pt'> </span>National<span
     style='letter-spacing:-.15pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.2pt'> </span>Centre<span style='letter-spacing:
     -.2pt'> (NPC)</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>SFDA<span
     style='letter-spacing:-.3pt'> </span>Call<span style='letter-spacing:-.2pt'>
     </span>Centre:<span style='letter-spacing:-.25pt'> </span><span
     style='letter-spacing:-.2pt'>19999</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>E-mail:<span
     style='letter-spacing:-.55pt'> </span></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:12.0pt;
     mso-bidi-font-size:11.0pt;color:#0563C2;letter-spacing:-.1pt;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>Website:<span
     style='letter-spacing:-.45pt'> </span><span style='color:#0563C2;
     letter-spacing:-.1pt'>https://ade.sfda.gov.sa/</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Other GCC States:</u></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="docshape5" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:126.55pt;margin-top:4.65pt;width:368.55pt;height:22.5pt;
  z-index:-15728128;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight="1pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:3.55pt;margin-right:0in;margin-bottom:
     0in;margin-left:.6in;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:.6in 43.25pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>•<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><i style='mso-bidi-font-style:
     normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>Please<span
     style='letter-spacing:-.3pt'> </span>contact<span style='letter-spacing:
     -.15pt'> </span>the<span style='letter-spacing:-.15pt'> </span>relevant<span
     style='letter-spacing:-.15pt'> </span>competent<span style='letter-spacing:
     -.1pt'> authority.</span><o:p></o:p></span></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. Based on limited data at doses above the recommended dose and up to 0.48 mg/kg the frequency of gastrointestinal disorders, vasovagal reactions, orthostatic hypotension, and/or syncope may be higher.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other immunostimulants; ATC code: L03AX16</p><p><u>Mechanism of action</u></p><p>Plerixafor is a bicyclam derivative, a selective reversible antagonist of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1&alpha; (SDF-1&alpha;), also known as CXCL12. Plerixafor-induced leukocytosis and elevations in circulating haematopoietic progenitor cell levels are thought to result from a disruption of CXCR4 binding to its cognate ligand, resulting in the appearance of both mature and pluripotent cells in the systemic circulation. CD34+ cells mobilised by plerixafor are functional and capable of engraftment with long-term repopulating capacity.</p><p><u>Pharmacodynamic effects</u></p><p>In pharmacodynamic studies in healthy volunteers of plerixafor alone, peak mobilisation of CD34+ cells was observed from 6 to 9 hours after administration. In pharmacodynamic studies in healthy volunteers of plerixafor in conjunction with G-CSF administered at identical dose</p><p>&nbsp;</p><p>regimen to that in studies in patients, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with peak response between 10 and 14 hours.</p><p>In order to compare the pharmacokinetics and pharmacodynamics of plerixafor following 0.24mg/kg based and fixed (20 mg) doses, a trial was conducted in adult patients with NHL (N=61) who were treated with 0.24 mg/kg or 20 mg of plerixafor. The trial was conducted in patients weighing 70 kg or less (median: 63.7 kg, min: 34.2 kg, max: 70 kg). The fixed 20 mg dose showed 1.43-fold higher exposure (AUC0-10h) than the 0.24 mg/kg dose (Table 2). The fixed 20 mg dose also showed numerically higher response rate (5.2% [60.0% vs 54.8%] based on the local lab data and 11.7% [63.3% vs 51.6%] based on the central lab data) in attaining the target of &ge; 5 &times; 10<sup>6</sup> CD34+ cells/kg than the mg/kg-based dose. The median time to reach</p><p>&ge; 5&times;10<sup>6</sup> CD34+ cells/kg was 3 days for both treatment groups, and the safety profile between the groups was similar. Body weight of 83 kg was selected as the cut-off point to transition patients from fixed to weight based dosing (83 kg x 0.24 mg = 19.92 mg/kg).</p><p>Table 2. Systemic Exposure (AUC0-10h) comparisons of fixed and weight based regimens</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Geometric Mean AUC</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fixed 20 mg (n=30)</p></td><td style="vertical-align:top"><p>3991.2</p></td></tr><tr><td style="vertical-align:top"><p>0.24 mg/kg (n=31)</p></td><td style="vertical-align:top"><p>2792.7</p></td></tr><tr><td style="vertical-align:top"><p>Ratio (90% CI)</p></td><td style="vertical-align:top"><p>1.43 (1.32,1.54)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Clinical efficacy and safety</u></p><p>In two Phase III randomised-controlled studies patients with non-Hodgkin&#39;s lymphoma or multiple myeloma received plerixafor 0.24 mg/kg or placebo on each evening prior to apheresis. Patients received daily morning doses of G-CSF 10 &mu;g/kg for 4 days prior to the first dose of plerixafor or placebo and on each morning prior to apheresis. Optimal (5 or 6x10<sup>6</sup> cells/kg) and minimal (2 x 10<sup>6</sup> cells/kg) numbers of CD34+ cells/kg within a given number of days, as well as the primary composite endpoints which incorporated successful engraftment are presented in Tables 3 and 5; the proportion of patients reaching optimal numbers of CD34+ cells/kg by apheresis day are presented in Tables 4 and 6.</p><p>Table 3. Study AMD3100-3101 efficacy results - CD34+ cell mobilisation in non-</p><p><strong>Hodgkin&#39;s lymphoma patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Efficacy endpoint<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Plerixafor and G-CSF</strong></p><p><strong>(n = 150)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo and G-CSF</strong></p><p><strong>(n = 148)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>p-value <sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients achieving &ge; 5 x 10<sup>6</sup> cells/kg in &le; 4</p><p>apheresis days and successful engraftment</p></td><td style="vertical-align:top"><p>86 (57.3%)</p></td><td style="vertical-align:top"><p>28 (18.9%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Patients achieving &ge; 2 x 10<sup>6</sup> cells/kg in &le; 4</p><p>apheresis days and successful engraftment</p></td><td style="vertical-align:top"><p>126 (84.0%)</p></td><td style="vertical-align:top"><p>64 (43.2%)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr></tbody></table><p>a: p-value calculated using Pearson&#39;s Chi-Squared test</p><p>b: Statistically significantly more patients achieved &ge; 5 x 106 cells/kg in &le; 4 apheresis days with plerixafor and G-CSF (n=89; 59.3%) than with placebo and G-CSF (n=29; 19.6%), p&lt;0.001; statistically significantly more patients achieved &ge; 2 x 106 cells/kg in &le; 4 apheresis days with plerixafor and G-CSF (n=130; 86.7%) than with placebo and G-CSF (n=70; 47.3%), p&lt;0.001.</p><p>Table 4. Study AMD3100-3101 &ndash; Proportion of patients who achieved &ge; 5 x 10<sup>6</sup> CD34+ cells/kg by apheresis day in non-Hodgkin&#39;s lymphoma patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Days</strong></p></td><td style="vertical-align:top"><p><strong>Proportion<sup>a</sup></strong></p><p><strong>in plerixafor and G-CSF (n=147<sup>b</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Proportion<sup>a</sup></strong></p><p><strong>in Placebo and G-CSF (n=142<sup>b</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1</strong></p></td><td style="vertical-align:top"><p>27.9%</p></td><td style="vertical-align:top"><p>4.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>49.1%</p></td><td style="vertical-align:top"><p>14.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>3</strong></p></td><td style="vertical-align:top"><p>57.7%</p></td><td style="vertical-align:top"><p>21.6%</p></td></tr><tr><td style="vertical-align:top"><p><strong>4</strong></p></td><td style="vertical-align:top"><p>65.6%</p></td><td style="vertical-align:top"><p>24.2%</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="docshape6" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='width:423pt;height:26.9pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokecolor="#7c7c7c"
 strokeweight=".72pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:1.55pt;margin-right:0in;margin-bottom:
    0in;margin-left:6.8pt;margin-bottom:.0001pt'><span style='font-size:10.0pt;
    mso-bidi-font-size:11.0pt'>a:<span style='letter-spacing:-.3pt'> </span>Percents<span
    style='letter-spacing:-.35pt'> </span>determined<span style='letter-spacing:
    -.25pt'> </span>by<span style='letter-spacing:-.25pt'> </span>Kaplan<span
    style='letter-spacing:-.25pt'> </span>Meier<span style='letter-spacing:
    -.25pt'> </span><span style='letter-spacing:-.1pt'>method</span><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
    0in;margin-left:6.8pt;margin-bottom:.0001pt'><span style='font-size:10.0pt;
    mso-bidi-font-size:11.0pt'>b:<span style='letter-spacing:-.2pt'> </span>n<span
    style='letter-spacing:-.15pt'> </span>includes<span style='letter-spacing:
    -.25pt'> </span>all<span style='letter-spacing:-.2pt'> </span>patients<span
    style='letter-spacing:-.2pt'> </span>who<span style='letter-spacing:-.15pt'>
    </span>received<span style='letter-spacing:-.15pt'> </span>at<span
    style='letter-spacing:-.2pt'> </span>least<span style='letter-spacing:-.15pt'>
    </span>one<span style='letter-spacing:-.2pt'> </span>day<span
    style='letter-spacing:-.15pt'> </span>of<span style='letter-spacing:-.3pt'>
    </span><span style='letter-spacing:-.1pt'>apheresis</span><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="569" height="41" alt="Text Box: a: Percents determined by Kaplan Meier method
b: n includes all patients who received at least one day of apheresis
" src="file:///C:/Users/L/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:423pt;height:26.9pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Table 5. Study AMD3100-3102 efficacy results &ndash; CD34+ cell mobilisation in multiple myeloma patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Efficacy endpoint<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Plerixafor and G-CSF (n = 1</strong>48<strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo and G-CSF</strong></p><p><strong>(n = 1</strong>54<strong>)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>p-value <sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients achieving &ge; 6 x 10<sup>6</sup> cells/kg in &le; 2</p><p>apheresis days and successful engraftment</p></td><td style="vertical-align:top"><p>104 (70.3%)</p></td><td style="vertical-align:top"><p>53 (34.4%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>a: p-value calculated using Cochran-Mantel-Haenszel statistic blocked by baseline platelet count</p><p>b: Statistically significantly more patients achieved &ge; 6 x 106 cells/kg in &le; 2 apheresis days with plerixafor and G-CSF (n=106; 71.6%) than with placebo and G-CSF (n=53; 34.4%), p&lt;0.001; statistically significantly more patients achieved &ge; 6 x 106 cells/kg in &le; 4 apheresis days with plerixafor and G-CSF (n=112; 75.7%) than with placebo and G-CSF (n=79; 51.3%), p&lt;0.001; statistically significantly more patients achieved &ge; 2 x 106 cells/kg in &le; 4 apheresis days with plerixafor and G-CSF (n=141; 95.3%) than with placebo and G-CSF (n=136; 88.3%), p=0.031.</p><p>Table 6. Study AMD3100-3102 &ndash; Proportion of patients who achieved &ge; 6 x 10<sup>6</sup> CD34+ cells/kg by apheresis day in multiple myeloma patients</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Days</strong></p></td><td style="vertical-align:top"><p><strong>Proportion</strong><sup>a</sup></p><p><strong>in plerixafor and G-CSF (n=144<sup>b</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Proportion</strong><sup>a</sup></p><p><strong>in Placebo and G-CSF (n=150<sup>b</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1</strong></p></td><td style="vertical-align:top"><p>54.2%</p></td><td style="vertical-align:top"><p>17.3%</p></td></tr><tr><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>77.9%</p></td><td style="vertical-align:top"><p>35.3%</p></td></tr><tr><td style="vertical-align:top"><p><strong>3</strong></p></td><td style="vertical-align:top"><p>86.8%</p></td><td style="vertical-align:top"><p>48.9%</p></td></tr><tr><td style="vertical-align:top"><p><strong>4</strong></p></td><td style="vertical-align:top"><p>86.8%</p></td><td style="vertical-align:top"><p>55.9%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a: Percents determined by Kaplan Meier method</p><p>b: n includes all patients who received at least one day of apheresis</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Rescue patients</em></p><p>In study AMD3100-3101, 62 patients (10 in the plerixafor + G-CSF group and 52 in the placebo + G-CSF group), who could not mobilise sufficient numbers of CD34+ cells and thus could not proceed to transplantation, entered into an open-label Rescue procedure with plerixafor and G-CSF. Of these patients, 55 % (34 out of 62) mobilised &ge; 2 x10<sup>6</sup>/kg CD34+ cells and had successful engraftment. In study AMD3100-3102, 7 patients (all from the placebo</p><p>+ G-CSF group) entered the Rescue procedure. Of these patients, 100% (7 out of 7) mobilised</p><p>&ge;2 x10<sup>6</sup>/kg CD34+ cells and had successful engraftment.</p><p>The dose of haematopoietic stem cells used for each transplant was determined by the investigator and all haematopoietic stem cells that were collected were not necessarily transplanted. For transplanted patients in the Phase III studies, median time to neutrophil engraftment (10-11 days), median time to platelet engraftment (18-20 days) and graft durability up to 12 months post-transplantation were similar across the plerixafor and placebo groups.</p><p>Mobilisation and engraftment data from supportive Phase II studies (plerixafor 0.24 mg/kg dosed on the evening or morning prior to apheresis) in patients with non-Hodgkin&#39;s lymphoma, Hodgkin&#39;s disease, or multiple myeloma were similar to those data for the Phase III studies.</p><p>In the placebo-controlled studies, fold increase in peripheral blood CD34+ cell count (cells/&mu;l) over the 24-hour period from the day prior to the first apheresis to just before the first apheresis was evaluated (Table 7). During that 24-hour period, the first dose of plerixafor 0.24 mg/kg or placebo was administered 10-11 hours prior to apheresis.</p><p>&nbsp;</p><p>Table 7. Fold increase in peripheral blood CD34+ cell count following plerixafor Iadministration</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Plerixafor and G-CSF</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo and G-CSF</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Median</strong></p></td><td style="vertical-align:top"><p><strong>Mean (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Median</strong></p></td><td style="vertical-align:top"><p><strong>Mean (SD)</strong></p></td></tr><tr><td style="vertical-align:top"><p>AMD3100-3101</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>6.1 (5.4)</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1.9 (1.5)</p></td></tr><tr><td style="vertical-align:top"><p>AMD3100-3102</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>6.4 (6.8)</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.4 (7.3)</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>The efficacy and safety of plerixafor were evaluated in an open label, multi-center, controlled study in paediatric patients with solid tumors (including neuroblastoma, sarcoma, Ewing sarcoma) or lymphoma who were eligible for autologous hematopoietic stem cell transplantation (DFI12860). Patients with leukemia, persistent high percentage marrow involvement prior to mobilization, or previous stem cell transplantation were excluded.</p><p>Forty-five paediatric patients (1 to less than 18 years) were randomised, 2:1, using 0.24 mg/kg of plerixafor plus standard mobilisation (G-CSF plus or minus chemotherapy) versus control (standard mobilisation alone). Median age was 5.3 years (min: max 1:18) in the plerixafor arm versus 4.7 years (min:max 1:17) in the control arm.</p><p>Only one patient aged less than 2 years old was randomized to the plerixafor treatment arm. There was an imbalance between treatment arms in peripheral blood CD34+ counts on the day prior to first apheresis (i.e. prior to administration of plerixafor), with less circulating PB CD34+ in the plerixafor arm. The median PB CD34+ cell counts at baseline were 15 cells/&micro;l in the plerixafor arm versus 35 cells/&micro;l in control arm. The primary analysis showed that 80% of patients in the plerixafor arm experienced at least a doubling of the PB CD34+ count, observed from the morning of the day preceding the first planned apheresis to the morning prior to apheresis, versus, 28.6 % of patients in the control arm (p=0.0019). The median increase in PB CD34+ cell counts from baseline to the day of apheresis was by 3.2 fold in the plerixafor arm versus by 1.4 fold in the control arm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of plerixafor have been evaluated in lymphoma and multiple myeloma patients at the clinical dose level of 0.24 mg/kg following pre-treatment with G-CSF (10 &mu;g/kg once daily for 4 consecutive days).</p><p><u>Absorption</u></p><p>Plerixafor is rapidly absorbed following subcutaneous injection, reaching peak concentrations in approximately 30-60 minutes (tmax). Following subcutaneous administration of a 0.24 mg/kg dose to patients after receiving 4-days of G-CSF pre-treatment, the maximal plasma concentration (Cmax) and systemic exposure (AUC0-24) of plerixafor were 887 &plusmn; 217 ng/ml and 4337 &plusmn; 922 ng&middot;hr/ml, respectively.</p><p><u>Distribution</u></p><p>Plerixafor is moderately bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 l/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space.</p><p><u>Biotransformation</u></p><p>Plerixafor is not metabolised <em>in vitro </em>using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity <em>in vitro </em>towards the major drug- metabolising CYP450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5). In <em>in vitro </em>studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, and CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in P450-dependent drug-drug interactions.</p><p><u>Elimination</u></p><p>The major route of elimination of plerixafor is urinary. Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted unchanged in urine during the first 24 hours following administration. The elimination half-life (t1/2) in</p><p>&nbsp;</p><p>plasma is 3-5 hours. Plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an <em>in vitro </em>study with MDCKII and MDCKII-MDR1 cell models.</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>Following a single dose of 0.24 mg/kg plerixafor, clearance was reduced in subjects with varying degrees of renal impairment and was positively correlated with creatinine clearance (CrCl). Mean values of AUC0-24 of plerixafor in subjects with mild (CrCl 51-80 ml/min), moderate (CrCl 31-50 ml/min) and severe (CrCl &le; 30 ml/min) renal impairment were 5410, 6780, and 6990 ng.hr/ml, respectively, which were higher than the exposure observed in healthy subjects with normal renal function (5070 ng&middot;hr/ml). Renal impairment had no effect on Cmax..</p><p><em>Gender</em></p><p>A population pharmacokinetic analysis showed no effect of gender on pharmacokinetics of plerixafor.</p><p><em>Elderly</em></p><p>A population pharmacokinetic analysis showed no effect of age on pharmacokinetics of plerixafor.</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of plerixafor were evaluated in 48 paediatric patients (1 to less than 18 years) with solid tumours at subcutaneous doses of 0.16, 0.24 and 0.32 mg/kg with standard mobilisation (G-CSF plus or minus chemotherapy). Based on population pharmacokinetic modeling and similar to adults, &micro;g/kg-based dosage results in increase in plerixafor exposure with increasing body weight in paediatric patients. At the same weight-based dosing regimen of 240 &micro;g/kg, the plerixafor mean exposure (AUC0-24h) is lower in paediatric patients aged 2 to &lt;6 years (1410 ng.h/mL), 6 to &lt;12 years (2318 ng.h/mL), and 12 to &lt;18 years (2981 ng.h/mL) than in adults (4337 ng.h/mL). Based on population pharmacokinetic modeling, the plerixafor mean exposures (AUC0-24h) in paediatric patients aged 2 to &lt;6 years (1905 ng.h/mL), 6 to &lt;12 years (3063 ng.h/mL), and 12 to &lt;18 years (4015 ng.h/mL), at the dose of 320 &micro;g/kg are closer to the exposure in adults receiving 240 &micro;g/kg.</p><p>However mobilization of PB CD34+ count was observed in stage 2 of the trial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results from single dose subcutaneous studies in rats and mice showed plerixafor can induce transient but severe neuromuscular effects (uncoordinated movement), sedative-like effects (hypoactivity), dyspnoea, ventral or lateral recumbency, and/or muscle spasms. Additional effects of plerixafor consistently noted in repeated dose animal studies included increased levels of circulating white blood cells and increased urinary excretion of calcium and magnesium in rats and dogs, slightly higher spleen weights in rats, and diarrhoea and tachycardia in dogs. Histopathology findings of extramedullary haematopoiesis were observed in the liver and spleen of rats and/or dogs. One or more of these findings were usually observed at systemic exposures in the same order of magnitude or slightly higher than the human clinical exposure.</p><p>The results of the dose range-finding study in juvenile miniature pigs and the range-finding and definitive studies in juvenile rats were similar to those observed in adult mice, rats, and dogs.</p><p>Exposure margins in the juvenile rat study at the maximum tolerated dose (MTD) were &ge;18</p><p>fold when compared with the highest clinical paediatric dose in children up to 18 years of age.</p><p>An <em>in vitro </em>general receptor activity screen showed that plerixafor, at a concentration (5 &micro;g/ml) several fold higher than the maximum human systemic level, has moderate or strong binding affinity for a number of different receptors predominantly located on pre-synaptic nerve endings in the central nervous system (CNS) and/or the peripheral nervous system (PNS) (N- type calcium channel, potassium channel SKCA, histamine H3, acetylcholine muscarinic M1 and M2, adrenergic &alpha;1B and &alpha;2C, neuropeptide Y/Y1 and glutamate NMDA polyamine receptors). The clinical relevance of these findings is not known.</p><p>&nbsp;</p><p>Safety pharmacology studies with intravenously administered plerixafor in rats showed respiratory and cardiac depressant effects at systemic exposure slightly above the human clinical exposure, whilst subcutaneous administration elicited respiratory and cardiovascular effects only at higher systemic levels.</p><p>SDF-1&alpha; and CXCR4 play major roles in embryo-foetal development. Plerixafor has been shown to cause increased resorptions, decreased foetal weights, retarded skeletal development and increased foetal abnormalities in rats and rabbits. Data from animal models also suggest modulation of foetal haematopoiesis, vascularisation, and cerebellar development by SDF-1&alpha; and CXCR4. Systemic exposure at No Observed Adverse Effect Level for teratogenic effects in rats and rabbits was of the same magnitude or lower as found at therapeutic doses in patients. This teratogenic potential is likely due to its pharmacodynamic mechanism of action.</p><p>In rat distribution studies concentrations of radiolabelled plerixafor was detected in reproductive organs (testes, ovaria, uterus) two weeks after single or 7 daily repeated doses in males and after 7 daily repeated doses in females. The elimination rate from tissues was slow.</p><p>The potential effects of plerixafor on male fertility and postnatal development have not been evaluated in non-clinical studies.</p><p>Carcinogenicity studies with plerixafor have not been conducted. Plerixafor was not genotoxic in an adequate battery of genotoxicity tests.</p><p>Plerixafor inhibited tumour growth in <em>in vivo </em>models of non-Hodgkin&#39;s lymphoma, glioblastoma, medulloblastoma, and acute lymphoblastic leukaemia when dosed intermittently. An increase of non-Hodgkin&#39;s lymphoma growth was noted after a continuous administration of plerixafor for 28 days. The potential risk associated with this effect is expected to be low for the intended short term duration of dosing plerixafor in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride Hydrochloric acid Sodium hydroxide Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial 2 years.

After opening

From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Keep out of the sight and reach of children.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hemabo is provided in a 2 mL USP type-1 clear tubular glass vial with 13 mm grey elastomer rubber stopper and sealed with 13 mm aluminum flip off seals having blue color plastic disc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company Tadawi Biomedical-KSA Riyadh, Sudair Industrial Area, Zone A, Road 11, Factory 107, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                xxxx
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>